Therapeutic efficacy of atovaquone-proguanil and artesunate-atovaquone-proguanil for the treatment of uncomplicated P. falciparum malaria in areas of multidrug resistance in Cambodia

Objectives

To evaluate the therapeutic efficacy, safety, tolerability and pharmacokinetics of a three-day course of Atovaquone-Proguanil (AP) or a three-day course of Atovaquone-Proguanil combined with 3 days of Artesunate (ASAP) in patients with uncomplicated Plasmodium falciparum malaria at selected sites in Cambodia